Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Targeted therapies

Time to shift the burden of proof for oncogene-positive cancer?

Rearrangements of the ALK gene have been associated with sensitivity to crizotinib and other kinase inhibitors with activity against ALK. The phase III PROFILE 1007 randomized study of crizotinib versus chemotherapy has demonstrated that crizotinib is superior to standard second-line chemotherapy in ALK-positive non-small-cell lung cancer.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

  1. Camidge, D. R. et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 13, 1011–1019 (2012).

    CAS  Article  Google Scholar 

  2. Kim, D. W. et al. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC) [abstract]. J. Clin. Oncol. 30 (Suppl.), a753 (2012).

    Google Scholar 

  3. Shaw, A. T. et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N. Engl. J. Med. 368, 2385–2394 (2013).

    CAS  Article  Google Scholar 

  4. Scagliotti, G. et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 14, 253–263 (2009).

    CAS  Article  Google Scholar 

  5. Camidge, D. R. et al. Anaplastic lymphoma kinase gene rearrangements in non-small cell lung cancer are associated with prolonged progression-free survival on pemetrexed. J. Thorac. Oncol. 6, 774–780 (2011).

    Article  Google Scholar 

  6. Mok, T. S. et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361, 947–957 (2009).

    CAS  Article  Google Scholar 

  7. Davies, K. D. & Doebele, R. C. Molecular pathways: ROS1 fusion proteins in cancer. Clin. Cancer Res. http://dx.doi.org/10.1158/1078-0432.CCR-12-2851.

  8. Ou, S. H. I. et al. Efficacy and safety of crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC) [abstract]. J. Clin. Oncol. 31 (Suppl.), a8032 (2013).

    Google Scholar 

  9. Awad, M. M. et al. Acquired resistance to crizotinib from a mutation in CD74-ROS1. N. Engl. J. Med. 368, 2395–2401 (2013).

    CAS  Article  Google Scholar 

  10. Camidge, D. R. & Doebele, R. C. Treating ALK-positive lung cancer--early successes and future challenges. Nat. Rev. Clin. Oncol. 9, 268–277 (2012).

    CAS  Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Robert C. Doebele.

Ethics declarations

Competing interests

The author has received research grants from Eli Lilly & Co., ImClone Systems and Pfizer, and advisory board and consulting fees from Boehringer Ingelheim and Pfizer.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Doebele, R. Time to shift the burden of proof for oncogene-positive cancer?. Nat Rev Clin Oncol 10, 492–493 (2013). https://doi.org/10.1038/nrclinonc.2013.135

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2013.135

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer